

# Sandra Vukusic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1119000/publications.pdf>

Version: 2024-02-01

68  
papers

11,005  
citations

159358

30  
h-index

102304

66  
g-index

69  
all docs

69  
docs citations

69  
times ranked

9010  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter. <i>Clinical Neuroradiology</i> , 2022, 32, 677-685.   | 1.0 | 3         |
| 2  | Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1155-1159.   | 1.4 | 13        |
| 3  | Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsingâ€“Remitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.  | 2.1 | 5         |
| 4  | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456. | 1.4 | 16        |
| 5  | Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.  | 3.1 | 30        |
| 6  | COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 5571-5581.   | 1.8 | 4         |
| 7  | Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1458-1463.  | 1.4 | 8         |
| 8  | Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.   | 0.6 | 24        |
| 9  | Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.  | 2.8 | 123       |
| 10 | Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 378-386.  | 2.1 | 5         |
| 11 | Cumulative effects of therapies on disability in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1760-1770.   | 1.4 | 11        |
| 12 | Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.   | 1.4 | 3         |
| 13 | Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.   | 1.7 | 8         |
| 14 | MRI findings in blinded trials should be available to treating physicians â€“ Yes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 812-813.   | 1.4 | 1         |
| 15 | Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1543-1555.  | 1.4 | 33        |
| 16 | Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. <i>Neurology</i> , 2021, 97, e403-e413.  | 1.5 | 10        |
| 17 | Update on brain MRI for the diagnosis and follow-up of MS patients. <i>Presse Medicale</i> , 2021, 50, 104067.  | 0.8 | 5         |
| 18 | Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.  | 1.5 | 15        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.  | 1.7 | 86        |
| 20 | Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.  | 2.7 | 8         |
| 21 | Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.  | 4.9 | 261       |
| 22 | MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103164.                    | 0.9 | 6         |
| 23 | Post-partum relapse in women with multiple sclerosis after neuraxial labour analgesia or neuraxial anaesthesia: A multicentre retrospective cohort study. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2021, 40, 100834. | 0.6 | 5         |
| 24 | Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset. <i>NeuroImage</i> , 2021, 244, 118589.  | 2.1 | 23        |
| 25 | Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2128271.  | 2.8 | 32        |
| 26 | Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 1001-1011.                   | 4.9 | 36        |
| 27 | Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. <i>Multiple Sclerosis Journal</i> , 2020, 26, 118-122.   | 1.4 | 69        |
| 28 | Spontaneous multiple cervical artery dissections after alemtuzumab. <i>Multiple Sclerosis Journal</i> , 2020, 26, 381-383.  | 1.4 | 14        |
| 29 | Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.                           | 1.4 | 37        |
| 30 | Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 829-836.                             | 1.4 | 39        |
| 31 | Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020, 77, 94.   | 4.5 | 36        |
| 32 | Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .   | 3.1 | 49        |
| 33 | Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1680-1688.   | 0.9 | 0         |
| 34 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.   | 3.7 | 24        |
| 35 | Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852097822.  | 1.4 | 3         |
| 36 | Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.  | 1.4 | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.  | 1.4 | 39        |
| 38 | Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.   | 4.5 | 357       |
| 39 | Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor. Multiple Sclerosis Journal, 2020, 26, 1610-1611.  | 1.4 | 0         |
| 40 | New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. Journal of Neuroradiology, 2020, 47, 250-258.               | 0.6 | 46        |
| 41 | Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology, 2019, 93, e635-e646.  | 1.5 | 36        |
| 42 | Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. Journal of Neurology, 2019, 266, 1743-1755.   | 1.8 | 9         |
| 43 | Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Current Opinion in Neurology, 2019, 32, 459-466.  | 1.8 | 38        |
| 44 | Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.  | 1.4 | 13        |
| 45 | Efficacy of rituximab in refractory RRMS. Multiple Sclerosis Journal, 2019, 25, 828-836.  | 1.4 | 28        |
| 46 | Cranial nerve involvement in patients with MOG antibody-associated disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e543.  | 3.1 | 53        |
| 47 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.   | 4.9 | 4,605     |
| 48 | Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.   | 1.5 | 401       |
| 49 | Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure. Scientific Reports, 2018, 8, 13650.   | 1.6 | 171       |
| 50 | Where there is inflammation, treatment may reduce disability progression – No. Multiple Sclerosis Journal, 2018, 24, 1810-1812.   | 1.4 | 1         |
| 51 | Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?. European Journal of Radiology, 2018, 105, 204-208. | 1.2 | 12        |
| 52 | Unusual neurologic presentation of aseptic abscesses syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e469.   | 3.1 | 1         |
| 53 | Multiple sclerosis broke my heart. Annals of Neurology, 2017, 81, 754-758.  | 2.8 | 22        |
| 54 | MOG antibody-related disorders: common features and uncommon presentations. Journal of Neurology, 2017, 264, 1945-1955.   | 1.8 | 119       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384. | 1.4  | 89        |
| 56 | Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey. <i>PLoS ONE</i> , 2017, 12, e0185104.      | 1.1  | 2         |
| 57 | MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1719-1731.         | 1.4  | 249       |
| 58 | Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. <i>Annals of Neurology</i> , 2016, 80, 791-791.                   | 2.8  | 1         |
| 59 | Risk of relapse after natalizumab withdrawal. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e297.  | 3.1  | 34        |
| 60 | Comparative efficacy of fingolimod vs natalizumab. <i>Neurology</i> , 2016, 86, 771-778.  | 1.5  | 71        |
| 61 | Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. <i>Neurology</i> , 2015, 85, 2076-2078.   | 1.5  | 28        |
| 62 | Multiple sclerosis and pregnancy in the 'treatment era'. <i>Nature Reviews Neurology</i> , 2015, 11, 280-289.   | 4.9  | 99        |
| 63 | Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 953-955.   | 1.4  | 35        |
| 64 | Natural history of multiple sclerosis: a unifying concept. <i>Brain</i> , 2006, 129, 606-616.   | 3.7  | 736       |
| 65 | Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 327-332.                                       | 0.6  | 97        |
| 66 | Pregnancy and multiple sclerosis (the PRIMs study): clinical predictors of postpartum relapse. <i>Brain</i> , 2004, 127, 1353-1360.   | 3.7  | 573       |
| 67 | Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. <i>Brain</i> , 2003, 126, 770-782.  | 3.7  | 839       |
| 68 | Relapses and Progression of Disability in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2000, 343, 1430-1438.  | 13.9 | 1,135     |